Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;40(1):75-101.
doi: 10.1007/s10545-016-9999-9. Epub 2016 Nov 16.

Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision

Collaborators, Affiliations
Review

Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision

Nikolas Boy et al. J Inherit Metab Dis. 2017 Jan.

Abstract

Glutaric aciduria type I (GA-I; synonym, glutaric acidemia type I) is a rare inherited metabolic disease caused by deficiency of glutaryl-CoA dehydrogenase located in the catabolic pathways of L-lysine, L-hydroxylysine, and L-tryptophan. The enzymatic defect results in elevated concentrations of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutaryl carnitine in body tissues, which can be reliably detected by gas chromatography/mass spectrometry (organic acids) and tandem mass spectrometry (acylcarnitines). Most untreated individuals with GA-I experience acute encephalopathic crises during the first 6 years of life that are triggered by infectious diseases, febrile reaction to vaccinations, and surgery. These crises result in striatal injury and consequent dystonic movement disorder; thus, significant mortality and morbidity results. In some patients, neurologic disease may also develop without clinically apparent crises at any age. Neonatal screening for GA-I us being used in a growing number of countries worldwide and is cost effective. Metabolic treatment, consisting of low lysine diet, carnitine supplementation, and intensified emergency treatment during catabolism, is effective treatment and improves neurologic outcome in those individuals diagnosed early; treatment after symptom onset, however, is less effective. Dietary treatment is relaxed after age 6 years and should be supervised by specialized metabolic centers. The major aim of this second revision of proposed recommendations is to re-evaluate the previous recommendations (Kölker et al. J Inherit Metab Dis 30:5-22, 2007b; J Inherit Metab Dis 34:677-694, 2011) and add new research findings, relevant clinical aspects, and the perspective of affected individuals.

PubMed Disclaimer

References

    1. Pediatr Radiol. 1999 Feb;29(2):138-43 - PubMed
    1. Mol Genet Metab. 2008 Jul;94(3):287-91 - PubMed
    1. Brain. 2009 Jul;132(Pt 7):1764-82 - PubMed
    1. Mol Genet Metab. 2012 Aug;106(4):430-8 - PubMed
    1. Pediatr Res. 2007 Sep;62(3):357-63 - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources